Category: ~$475M

  • Alcon to Acquire Ivantis for ~$475M

    Shots: Ivantis to receive $475M up front along with additional payments upon achievement of regulatory & commercial milestones. The transaction is expected to close in Q1’22 The acquisition expands Alcon’s surgical portfolio & uses the commercial execution expertise across cataract, refractive, retina & glaucoma. Hydrus Microstent is approved for use in conjunction with cataract surgery […]